Cefepime/piperacillin/tazobactamDevelopment of drug resistance and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1943卷 / 1期

关键词：

D O I：

10.1007/s40278-023-33077-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：192 / 192

相关论文

共 50 条

[11] BamlanivimabAcquired resistance and off-label use: case report
[J]. Reactions Weekly, 2023, 1938 (1) : 302 - 302
[12] Dexamethasone/piperacillin/tazobactam/remdesivirLack of efficacy and off-label use: case report
[J]. Reactions Weekly, 2023, 1956 (1) : 184 - 184
[13] Dexamethasone/piperacillin/tazobactamLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2021, 1867 (1) : 153 - 153
[14] Metformin/piperacillin/tazobactam/propacetamolLack of efficacy and off-label use: case report
[J]. Reactions Weekly, 2022, 1911 (1) : 272 - 272
[15] TrametinibAcquired drug resistance with off-label treatment: case report
[J]. Reactions Weekly, 2019, 1774 (1) : 298 - 298
[16] LarotrectinibAcquired drug resistance and liver toxicity following off-label use: case report
[J]. Reactions Weekly, 2023, 1978 (1) : 221 - 221
[17] Cefepime/gentamicin/linezolidPeripheral neuropathy, off-label use and lack of efficacy: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 175 - 175
[18] Inotuzumab ozogamicinDevelopment of resistance and off-label use: case report
[J]. Reactions Weekly, 2019, 1783 (1) : 147 - 147
[19] DalbavancinDrug-resistance and off-label use: case report
[J]. Reactions Weekly, 2019, 1734 (1) : 170 - 170
[20] Azacitidine/olaparibDrug resistance and off-label use: case report
[J]. Reactions Weekly, 2022, 1904 (1) : 92 - 92

← 1 2 3 4 5 →